Exhibit 99.1 EUPRAXIA PHARMACEUTICALS INC. CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months ended June 30, 2024 (Unaudited and Expressed in U.S. Dollars) EUPRAXIA PHARMACEUTICALS INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 (Unaudited and Expressed in U.S. Dollars) | | Three months | | Three months | | Six months | | Six months | | --- | --- | --- | --- | --- | --- | --- | --- | | | ended June 30, | | ended June 30, | | ended June 30, | | ended June 30, | | | 2024 | | 2023 | | ...

Exhibit 99.1 Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results Victoria, B.C. - April 1, 2024 - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results (prepared in accordance with U.S. GAAP) and operational highlights for the fourth quarter ended December 31, 2023. All ...